The estimated Net Worth of Richard P Shea is at least $2.34 Миллион dollars as of 13 December 2019. Mr. Shea owns over 7,500 units of Synlogic Inc stock worth over $10,350 and over the last 20 years he sold SYBX stock worth over $2,230,763. In addition, he makes $94,971 as Independent Director at Synlogic Inc.
Richard has made over 96 trades of the Synlogic Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 7,500 units of SYBX stock worth $20,550 on 13 December 2019.
The largest trade he's ever made was exercising 46,728 units of Synlogic Inc stock on 15 June 2012 worth over $28,504. On average, Richard trades about 1,894 units every 34 days since 2005. As of 13 December 2019 he still owns at least 7,500 units of Synlogic Inc stock.
You can see the complete history of Mr. Shea stock trades at the bottom of the page.
Richard P. Shea serves as Independent Director of the Company. Mr. Shea has served as the Chief Financial Officer of Syndax Pharmaceuticals, Inc. since February 2017. Mr. Shea previously served as a member of the Syndax Pharmaceuticals board of directors from January 2014 to February 2017. From July 2007 through December 2016, Mr. Shea served as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals Inc., a publicly-traded biotechnology company, and was its Vice President and Chief Financial Officer since October 2003. Prior to joining Momenta, Mr. Shea served as Chief Operating Officer and Chief Financial Officer of Variagenics Inc., a publicly-traded pharmacogenomics company, that was merged with Hyseq Pharmaceuticals Inc., and as Vice President, Finance of Genetics Institute, Inc., a publicly-traded biotechnology company, which was acquired by Wyeth Pharmaceuticals, Inc., which was then acquired by Pfizer, Inc. Mr. Shea received an A.B. from Princeton University and an M.B.A. from the Public Management Program at Boston University. The Board has concluded Mr. Shea possesses specific attributes that qualify him to serve as a member of our Board, including his experience with the healthcare and pharmaceutical industries and his broad life sciences industry knowledge.
As the Independent Director of Synlogic Inc, the total compensation of Richard Shea at Synlogic Inc is $94,971. There are 6 executives at Synlogic Inc getting paid more, with Aoife Brennan having the highest compensation of $1,793,870.
Richard Shea is 68, he's been the Independent Director of Synlogic Inc since 2017. There are no older and 16 younger executives at Synlogic Inc.
Richard's mailing address filed with the SEC is C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE, MA, 02142.
Over the last 7 years, insiders at Synlogic Inc have traded over $330,991 worth of Synlogic Inc stock and bought 17,000 units worth $31,190 . The most active insiders traders include Forest Baskett, Scott D Sandell и Anthony A. Jr. Florence. On average, Synlogic Inc executives and independent directors trade stock every 132 days with the average trade being worth of $7,257. The most recent stock trade was executed by Mary Beth Dooley on 2 April 2024, trading 188 units of SYBX stock currently worth $325.
at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre
Synlogic Inc executives and other stock owners filed with the SEC include: